244 related articles for article (PubMed ID: 16485129)
1. Complement decay accelerating factor (DAF)/CD55 in cancer.
Spendlove I; Ramage JM; Bradley R; Harris C; Durrant LG
Cancer Immunol Immunother; 2006 Aug; 55(8):987-95. PubMed ID: 16485129
[TBL] [Abstract][Full Text] [Related]
2. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells.
Iborra A; Mayorga M; Llobet N; Martínez P
Cell Immunol; 2003 May; 223(1):46-51. PubMed ID: 12914757
[TBL] [Abstract][Full Text] [Related]
3. Costimulation via CD55 on human CD4+ T cells mediated by CD97.
Capasso M; Durrant LG; Stacey M; Gordon S; Ramage J; Spendlove I
J Immunol; 2006 Jul; 177(2):1070-7. PubMed ID: 16818763
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55.
Abbott RJ; Spendlove I; Roversi P; Fitzgibbon H; Knott V; Teriete P; McDonnell JM; Handford PA; Lea SM
J Biol Chem; 2007 Jul; 282(30):22023-32. PubMed ID: 17449467
[TBL] [Abstract][Full Text] [Related]
5. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.
Schmitt CA; Schwaeble W; Wittig BM; Meyer zum Büschenfelde KH; Dippold WG
Eur J Cancer; 1999 Jan; 35(1):117-24. PubMed ID: 10211099
[TBL] [Abstract][Full Text] [Related]
6. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo.
van den Wijngaard RM; Asghar SS; Pijnenborg AC; Tigges AJ; Westerhof W; Das PK
Br J Dermatol; 2002 Jan; 146(1):80-7. PubMed ID: 11841370
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line.
Bjørge L; Jensen TS; Matre R
Cancer Immunol Immunother; 1996 Mar; 42(3):185-92. PubMed ID: 8640847
[TBL] [Abstract][Full Text] [Related]
9. Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation.
Terstappen LW; Nguyen M; Lazarus HM; Medof ME
J Leukoc Biol; 1992 Dec; 52(6):652-60. PubMed ID: 1281489
[TBL] [Abstract][Full Text] [Related]
10. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
[TBL] [Abstract][Full Text] [Related]
11. The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy.
Mikesch JH; Schier K; Roetger A; Simon R; Buerger H; Brandt B
Cell Oncol; 2006; 28(5-6):223-32. PubMed ID: 17167176
[TBL] [Abstract][Full Text] [Related]
12. bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction.
Mason JC; Lidington EA; Ahmad SR; Haskard DO
Am J Physiol Cell Physiol; 2002 Mar; 282(3):C578-87. PubMed ID: 11832343
[TBL] [Abstract][Full Text] [Related]
13. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
Gelderman KA; Blok VT; Fleuren GJ; Gorter A
Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
[TBL] [Abstract][Full Text] [Related]
14. Decay-accelerating factor regulates T-cell immunity in the context of inflammation by influencing costimulatory molecule expression on antigen-presenting cells.
Fang C; Miwa T; Song WC
Blood; 2011 Jul; 118(4):1008-14. PubMed ID: 21652682
[TBL] [Abstract][Full Text] [Related]
15. Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.
Kwon YC; Kim H; Meyer K; Di Bisceglie AM; Ray R
J Immunol; 2016 Aug; 197(4):1127-36. PubMed ID: 27357152
[TBL] [Abstract][Full Text] [Related]
16. Complement-regulatory proteins in ovarian malignancies.
Bjørge L; Hakulinen J; Wahlström T; Matre R; Meri S
Int J Cancer; 1997 Jan; 70(1):14-25. PubMed ID: 8985085
[TBL] [Abstract][Full Text] [Related]
17. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.
Harris CL; Spiller OB; Morgan BP
Immunology; 2000 Aug; 100(4):462-70. PubMed ID: 10929073
[TBL] [Abstract][Full Text] [Related]
18. Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55).
Bergelson JM; Mohanty JG; Crowell RL; St John NF; Lublin DM; Finberg RW
J Virol; 1995 Mar; 69(3):1903-6. PubMed ID: 7531780
[TBL] [Abstract][Full Text] [Related]
19. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement.
White DJ; Oglesby T; Liszewski MK; Tedja I; Hourcade D; Wang MW; Wright L; Wallwork J; Atkinson JP
Transpl Int; 1992; 5 Suppl 1():S648-50. PubMed ID: 14621899
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma.
Gelderman KA; Kuppen PJ; Bruin W; Fleuren GJ; Gorter A
Eur J Immunol; 2002 Jan; 32(1):128-35. PubMed ID: 11754353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
